Invesco Mutual Fund Launches ‘Invesco India Pharma and Healthcare Fund’ Main Content

To capture the growth opportunities within India’s rapidly expanding healthcare and pharmaceutical sectors, Invesco Mutual Fund has launched a new open-ended equity scheme titled the Invesco India Pharma and Healthcare Fund.

Investment Sectors & Market Drivers:
Driven by shifting lifestyles, rising health insurance coverage, growing purchasing power, an aging demographic, and international recognition for the Indian pharmaceutical sector, this fund targets multiple growth verticals. The scheme invests across pharmaceutical companies, hospitals, diagnostics centers, contract research and manufacturing organizations (CDMOs/CROs), medical device manufacturers, and the health insurance sector.

Investment Strategy & Management:
Managed by Aditya Khemani, Head of Equity and Fund Manager at Invesco Mutual Fund, the scheme is benchmarked against the BSE Healthcare TRI index. Highlighting a structural shift in the healthcare sector, Khemani noted that India is rapidly emerging as a global center for pharmaceutical and healthcare innovation, with the fund strategy focusing on selecting quality companies to deliver long-term returns across this multi-year growth cycle.

NFO Details & Structure:
The New Fund Offer (NFO) period runs from August 18, 2026, to September 1, 2026. Key structural details include:

Minimum Investment (Lump sum): Rs. 1,000

Minimum Investment (SIP): Rs. 100

Exit Load: 0.50% if units are redeemed within 3 months of allotment; zero exit load after 3 months.